United Therapeutics Corporation

Equities

UTHR

US91307C1027

Market Closed - Nasdaq Other stock markets 16:00:00 2026-05-14 EDT			5-day change	1st Jan Change
575.79 ^USD	-0.65%		+1.16%	+18.17%

05-14	United Therapeutics Insider Sold Shares Worth $5,497,166, According to a Recent SEC Filing	MT
05-13	Varda Space Industries And United Therapeutics Collaborate To Advance Microgravity-Enabled Treatments For Rare Pulmonary Disease	CI

Transcript : United Therapeutics Corporation Presents at TD Cowen 45th Annual Healthcare Conference, Mar-03-2025 01

Published on 03/03/2025 at 01:50 pm EST

S&P Capital IQ

Presenter Speech
Joseph Thome (Analysts)

[Audio Gap]

President and COO, Mike Benkowitz. So Mike, thank you very much for joining us. And maybe just to kick things off,

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about United Therapeutics Corporation

05-14	United Therapeutics Insider Sold Shares Worth $5,497,166, According to a Recent SEC Filing	MT
05-13	Varda Space Industries And United Therapeutics Collaborate To Advance Microgravity-Enabled Treatments For Rare Pulmonary Disease	CI
05-13	United Therapeutics, Varda to Study Space-Based Drug Manufacturing for Pulmonary Disease Treatments	MT
05-13	Varda Space Industries and United Therapeutics collaborate to advance microgravity-enabled treatments for rare pulmonary disease	RE
05-11	United Therapeutics Corporation Presents New Data from TETON-1, Advance Outcomes, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis	CI
05-11	United Therapeutics Insider Sold Shares Worth $5,496,084, According to a Recent SEC Filing	MT
05-11	United Therapeutics Insider Sold Shares Worth $5,785,775, According to a Recent SEC Filing	MT
05-07	United Therapeutics Insider Sold Shares Worth $5,600,468, According to a Recent SEC Filing	MT
05-07	United Therapeutics Insider Sold Shares Worth $4,870,054, According to a Recent SEC Filing	MT
05-07	United Therapeutics Growth Outlook Remains Supported by Tyvaso, Ralinepag, RBC Says	MT
05-07	RBC Capital Adjusts United Therapeutics Price Target to $701 From $707, Maintains Outperform Rating	MT
05-07	Wells Fargo Upgrades United Therapeutics to Overweight From Equalweight, Raises Price Target to $738 From $575	MT
05-07	Morgan Stanley Trims Price Target on United Therapeutics to $516 From $519, Keeps Equalweight Rating	MT
05-06	United Therapeutics Corporation, Q1 2026 Earnings Call, May 06, 2026
05-06	United Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI